AzTrials
AzTrials

Non Small Cell Lung CancerPhase 2NCT05312840

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

A Phase 2 study testing Cisplatin / Carboplatin，Gemcitabine，Sintilimab in people with Non Small Cell Lung Cancer, run by People's Hospital of Quzhou at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To observe the efficacy and safety of conventional and low-dose platinum Gemcitabine combined with Sintilimab with delayed administration in first-line treatment of advanced squamous non-small cell lung cancer. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Non Small Cell Lung Cancer
What is being tested?
Cisplatin / Carboplatin，Gemcitabine，Sintilimab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteChina
Study dates
1 Jan 2022to 31 Dec 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Sign written informed consent before implementing any test related process.
  • Age ≥ 18 years old and ≤ 75 years old.
  • Subjects with histologically or cytologically confirmed locally advanced (iiib-iiic), metastatic or recurrent (stage IV) squamous NSCLC (TNM lung cancer staging, 8th Edition, International Association for the study of lung cancer and Joint Committee on American Classification of cancer), inoperable and radical concurrent radiotherapy and chemotherapy, and who have not received systematic treatment before.
  • The gene status is unknown, or the gene status of known histological specimens confirms that there is no EGFR gene sensitive mutation or ALK gene fusion mutation.
  • According to the evaluation criteria of solid tumor efficacy (RECIST v1.1), at least one lesion can be measured by imaging. Lesions located in the radiation field of previous radiotherapy can be regarded as measurable lesions if they are confirmed to have progression.
  • Have not received any systematic antitumor treatment for advanced / metastatic diseases in the past. Subjects who have previously received platinum containing adjuvant / neoadjuvant chemotherapy or radical chemoradiotherapy for advanced diseases, if the interval between disease progression or recurrence and the end of the last chemotherapeutic drug treatment is at least 6 months, are allowed to be included in this study.
Show all 13Show fewer
  • Subjects with brain metastases who are asymptomatic or have stable symptoms after local treatment are allowed to be included as long as they meet the following conditions: 1) measurable lesions outside the central nervous system, 2) no symptoms of the central nervous system or no aggravation of symptoms for at least 2 weeks, 3) no glucocorticoid treatment is required, or glucocorticoid treatment is stopped within 7 days before the first administration, Or the dosage of glucocorticoid is stable and reduced to less than 10mg / day prednisone (or equivalent dose) within 7 days before the first administration.
  • Patients were allowed to receive palliative radiotherapy, but the end time of radiotherapy was 7 days before the administration of the first study drug, and the toxicity related to radiotherapy recovered to less than or equal to grade 1 (CTCAE V5.0).
  • ECoG score: 0-1.
  • Expected survival time > 3 months.
  • For adequate organ function, the subjects shall meet the following laboratory indexes: 1) the absolute value of neutrophils (ANC) ≥ 1.5x109/l without granulocyte colony stimulating factor in recent 14 days; 2) Platelets ≥ 100 without blood transfusion in recent 14 days × 109/L 3) Hemoglobin > 9g / dl without blood transfusion or erythropoietin in recent 14 days; 4) Total bilirubin ≤ 1.5 times the upper limit of normal value (ULN) 5) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are ≤ 2.5 times ULN (ALT or AST ≤ 5 is allowed for subjects with liver metastasis × ULN） 6) Serum creatinine ≤ 1.5 times ULN and creatinine clearance rate (calculated by Cockcroft Gault formula) ≥ 60 ml / min; 7) Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN; 8) Normal thyroid function is defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH is beyond the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled; 9) The myocardial enzyme spectrum is within the normal range (for example, simple laboratory abnormalities that are not clinically significant according to the comprehensive judgment of the researcher are also allowed to be included in the group).
  • For female subjects of childbearing age, urine or serum pregnancy test shall be conducted within 3 days before receiving the first study drug administration (day 1 of cycle 1) and the result is negative. If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Women of non childbearing age are defined as having been postmenopausal for at least 1 year or having undergone surgical sterilization or hysterectomy.
  • If there is a risk of pregnancy, all subjects (male or female) are required to use contraceptives with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last study drug administration (or 180 days after the last study drug administration).

Who cannot join

  • Pathology is adenocarcinoma or small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC.
  • Received radiotherapy before administration of the first study drug, Meet one of the following conditions: 1) more than 30% of bone marrow had received radiotherapy within 14 days before treatment; 2) received radiotherapy for lung lesions within 6 weeks before treatment and the dose was > 30Gy (the enrolled subjects must recover from the toxicity of previous radiotherapy to grade 1 or below, do not need glucocorticoid treatment and have no history of radiation pneumonia) 3) The end time of palliative radiotherapy was within 7 days before the administration of the first study drug.
  • Other malignant diseases other than NSCLC diagnosed within 5 years before the first administration (excluding radical skin basal cell carcinoma, skin squamous epithelial carcinoma, and / or radical resection of carcinoma in situ).
  • Currently participating in intervention clinical research treatment, or receiving other research drugs or using research instruments within 4 weeks before the first administration.
  • Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or co inhibit T cell receptors (e.g., CTLA-4, OX-40, CD137).
  • Received systemic treatment with Chinese patent medicine with anti NSCLC indications or drugs with immunomodulatory effect (including thymosin, interferon and interleukin, except for local use to control pleural effusion) within 2 weeks before the first administration.
Show all 19Show fewer
  • Active autoimmune diseases requiring systemic treatment (such as the use of disease relief drugs, glucocorticoids or immunosuppressants) occurred within 2 years before the first administration. Alternative therapies (such as thyroxine, insulin or physiological glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic treatment.
  • Being treated with systemic glucocorticoids (excluding nasal spray, inhaled or other local glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first administration of the study; Note: it is allowed to use glucocorticoids in physiological doses (≤ 10 mg / day prednisone or equivalent).
  • There is clinically uncontrollable pleural effusion / peritoneal effusion (subjects who do not need to drain effusion or stop drainage for 3 days and have no significant increase in effusion can be enrolled).
  • Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
  • Those who are known to be allergic to active ingredients or excipients such as Sintilimab, pemetrexed, gemcitabine, carboplatin and cisplatin.
  • Not fully recovered from toxicity and / or complications caused by any intervention before starting treatment (i.e. ≤ grade 1 or reaching baseline, excluding fatigue or hair loss).
  • Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1 / 2 antibody positive).
  • untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number at the same time was higher than the upper limit of normal value in the laboratory of the research center). Note: hepatitis B patients who met the following criteria can also be admitted into the group: 1) HBV viral load <1000 copy /ml (200 IU/ml) before the first dose, the subjects should receive anti HBV therapy to avoid reactivation of the virus during the whole course of chemotherapy (2). Subjects with anti HBc (+), HBsAg (-), anti HBs (-) and HBV viral load (-), Prophylactic anti HBV treatment is not required, but virus reactivation needs to be closely monitored.
  • Active HCV infected subjects (HCV antibody positive and HCV-RNA level above the lower limit of detection).
  • Have received live vaccine within 30 days before the first administration (cycle 1, day 1); Note: it is allowed to receive inactivated virus vaccine for injection against seasonal influenza within 30 days before the first administration; However, live attenuated influenza vaccines administered intranasal are not allowed.
  • Pregnant or lactating women.
  • There are any serious or uncontrollable systemic diseases, such as: 1) there are significant abnormalities in rhythm, conduction or morphology of resting ECG and the symptoms are serious and difficult to control, such as complete left bundle branch block, heart block above grade II, ventricular arrhythmia or atrial fibrillation; 2) Unstable angina pectoris, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) grade ≥ 2; 3) Myocardial infarction occurred within 6 months before enrollment; 4) Poor blood pressure control (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg); 5) A history of noninfectious pneumonia requiring glucocorticoid treatment within 1 year before the first administration, or the current presence of clinically active interstitial lung disease; 6) Active pulmonary tuberculosis; 7) There are active or uncontrolled infections requiring systemic treatment; 8) There were clinically active diverticulitis, abdominal abscess and gastrointestinal obstruction; 9) Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis; 10) poor control of diabetes (fasting blood glucose (FBG) > 10mmol/L). 11) Urine routine examination showed that urinary protein was ≥ + +, and the 24-hour urinary protein was confirmed to be more than 1.0 g; 12) Subjects with mental disorders and unable to cooperate with treatment.
  • There is no evidence that the participants in the study group have abnormal medical history or other potential conditions that may hinder the study group from participating in the study.

Trial locations and contacts

1 site in 1 country.

China1 site

  • Quzhou people's Hospital

    Quzhou, Zhejiang

Other trials in China

About this study

To observe the efficacy and safety of conventional and low-dose platinum Gemcitabine combined with Sintilimab with delayed administration in first-line treatment of advanced squamous non-small cell lung cancer.

Read the detailed description

At present, Sintilimab combined with Gemcitabine and platinum chemotherapy has obtained the indication of first-line treatment for patients with advanced squamous non-small cell lung cancer, and has become one of the standard first-line treatment schemes for patients with advanced squamous non-small cell lung cancer. However, in DRIENT12 study, although it was confirmed that Sintilimab combined with Gemcitabine and platinum chemotherapy regimen can further delay or prevent the growth of cancer cells compared with placebo combined with Gemcitabine and platinum, in the process of treatment, due to serious adverse drug reactions, a considerable number of patients need to reduce the therapeutic dose of therapeutic drugs, and the body function of patients is damaged in this process, It will inevitably affect the treatment cycle, and even some patients stop treatment due to serious adverse drug reactions, and the serious adverse reactions of chemotherapy drugs will destroy the immune microenvironment, which will eventually affect the efficacy of the anti-cancer treatment. In addition, the mechanism of action of Sintilimab is different from that of chemotherapeutic drugs. It can kill tumor cells and inhibit tumor growth by activating human immune function. Therefore, in the combined scheme, reducing the dose of chemotherapy drugs to avoid too strong side effects damaging human immune function, destroying tumor cells to release antigens after the use of chemotherapy drugs, and continuing PD-1 monoclonal antibody to enhance human anti-tumor immunity may achieve the equivalent or better anti-tumor efficacy obtained in ORIENT12 research, and reduce treatment-related adverse reactions at the same time.

Being tested
Cisplatin / Carboplatin，Gemcitabine，Sintilimab
Medical subject headings
Carcinoma, Non-Small-Cell Lung

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cisplatin / Carboplatin，Gemcitabine，SintilimabDrug

    1. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Sintilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Sintilimab 200mg were injected intravenously.
Study groups in NCT05312840
Study groupRoleWhat they receive
Routine dose groupOtherRoutine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2, Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Sintilimab 200mg were injected intravenously on the eighth day. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Sintilimab 200mg every three weeks until the disease progresses.
Receives: Drug: Cisplatin / Carboplatin，Gemcitabine，Sintilimab
Low dose groupOtherLow dose group: Every three weeks as a cycle. Gemcitabine 750mg / m2, Cisplatin 56mg / m2 or Carboplatin auc3 were injected intravenously on the first day of each cycle 75. On the eighth day, Gemcitabine 750mg / m2 and Sintilimab 200mg were injected intravenously. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Sintilimab 200mg every three weeks until the disease progresses.
Receives: Drug: Cisplatin / Carboplatin，Gemcitabine，Sintilimab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The objective response rate (ORR) of treatment was evaluated according to RECIST (v1.1).

    To evaluate the objective response rate (ORR) of subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Sintilimab with delayed administration in first-line treatment. ORR is defined as the proportion of subjects with complete response (CR) and partial response (PR) in the total subjects.

    Measured: 36 months

  2. Assess the subject's progression free survival (PFS) according to RECIST (v1.1).

    To evaluate the progression free survival (PFS) of subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Sintilimab with delayed administration in first-line treatment. PFS is defined as the time from the beginning of treatment to the first imaging disease progression or death, whichever occurs first.

    Measured: 36 months

  3. Assess the subject's disease control rate (DCR) according to RECIST (v1.1).

    To evaluate the disease control rate (DCR) of subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Sintilimab with delayed administration in first-line treatment. DCR is defined as the proportion of total subjects with complete remission (CR), partial remission (PR) and disease stability (SD).

    Measured: 36 months

  4. The duration of remission (DOR) was assessed according to RECIST (v1.1).

    To evaluate the duration of remission (DOR) of subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Sintilimab with delayed administration in first-line treatment. DOR is defined as the time interval from the first recorded remission to disease progression or death, whichever occurs first.

    Measured: 36 months

  5. The overall survival (OS) of the subjects was evaluated according to RECIST (v1.1).

    To evaluate the overall survival (OS) of subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Sintilimab with delayed administration in first-line treatment. OS is defined as the time from the beginning of treatment to the death of subjects from any cause.

    Measured: 36 months

Secondary outcomes (1)

  1. The incidence of adverse events was evaluated according to NCI CTCAE (v5.0).

    To evaluate the incidence of adverse events in subjects with advanced squamous non-small cell lung cancer treated with conventional and low-dose platinum Gemcitabine combined with Sintilimab with delayed administration in first-line treatment.

    Measured: 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Apr 2022
  2. Study start1 Jan 2022
  3. Primary completion31 Dec 2024
  4. Study completion31 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05312840
Sponsor's protocol ID
320.6750.2021-02-135
Status last verified
Sep 2026
First submitted
14 Mar 2022
Last updated
23 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Cisplatin / Carboplatin，Gemcitabine，Sintilimab in people with Non Small Cell Lung Cancer, run by People's Hospital of Quzhou at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The objective response rate (ORR) of treatment was evaluated according to RECIST (v1.1). (time frame: 36 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05312840.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in